Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

COVAX expects full vaccine supplies from India's Serum in May, says UNICEF

Published 03/27/2021, 02:42 PM
Updated 03/27/2021, 02:45 PM
© Reuters. FILE PHOTO: Vaccination against the coronavirus disease (COVID-19) in Grevesmuehlen

© Reuters. FILE PHOTO: Vaccination against the coronavirus disease (COVID-19) in Grevesmuehlen

By Krishna N. Das

NEW DELHI (Reuters) - A World Health Organization (WHO)-backed programme to supply coronavirus vaccines to poorer countries expects that the Serum Institute of India (SII) will resume full deliveries of the AstraZeneca (NASDAQ:AZN) shot to it in May, UNICEF said on Saturday.

"Deliveries of SII/AZ vaccine are expected to begin fully again by May, with catch-up deliveries to reach every participant’s full allocation up to May, accelerating thereafter," a UNICEF spokeswoman told Reuters in an email.

The spokeswoman added that the programme, known as COVAX, was in talks with New Delhi to secure "some supply" in April too. COVAX was expecting a total of 90 million doses from SII in March and April, of which it has received about 28 million.

UNICEF is the distributing partner of the programme, run with the GAVI vaccine alliance.

India, the world's biggest vaccine maker, said on Friday it would make domestic COVID-19 inoculations a priority as infections surge, and had told international buyers of its decision.

WHO Director-General Tedros Adhanom Ghebreyesus said on Friday that India's decision was "understandable" but that the WHO was in talks so it continues providing doses to other countries.

© Reuters. FILE PHOTO: Vaccination against the coronavirus disease (COVID-19) in Grevesmuehlen

So far COVAX has delivered 32 million vaccine doses to 61 countries, but 36 countries still await vaccines to start inoculations, Tedros said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.